Trials / Unknown
UnknownNCT03300765
Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer
Intensity Modulated Radiation Therapy Combined With Apatinib for Inoperable or Iodine Refractory Thyroid Cancer: A Phase II Single-arm Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Xiayun He, MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy and safety of intensity modulated radiation therapy combined with apatinib for inoperable or iodine refractory thyroid cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib will be used as induction therapy in experimental arm. |
| RADIATION | Intensity modulated radiation therapy | Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy. |
Timeline
- Start date
- 2017-07-01
- Primary completion
- 2019-07-01
- Completion
- 2020-05-01
- First posted
- 2017-10-03
- Last updated
- 2017-10-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03300765. Inclusion in this directory is not an endorsement.